Smith Brandi, Rajapakse Nipunie, Sauer Hannah E, Ellsworth Kevin, Dinnes Laura, Madigan Theresa
From the Department of Pharmacy, Mayo Clinic, Rochester, Minnesota.
Division of Pediatric Infectious Diseases, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota.
Pediatr Qual Saf. 2022 Jul 18;7(4):e579. doi: 10.1097/pq9.0000000000000579. eCollection 2022 Jul-Aug.
Invasive candidiasis has a high morbidity and mortality among premature neonates. Antifungal prophylaxis with fluconazole significantly lowers the risk of invasive fungal infection in this population. We noted the use of fluconazole prophylaxis in our level IV neonatal intensive care unit (NICU) was variable and sought to standardize prescribing of prophylactic fluconazole.
We formed a multidisciplinary team to develop an evidence-based protocol using literature and expert consensus to guide appropriate use of fluconazole prophylaxis in our level IV NICU. After determining baseline fluconazole prophylaxis prescribing before protocol implementation, we used plan-do-study-act (PDSA) cycles to introduce protocolized prescribing and incorporate it into daily practice. A 6-month intervention phase was followed by a 2-year control phase, in which monthly audits were performed to evaluate protocol adherence. Results were displayed in a statistical process control chart.
Before protocol implementation, fluconazole prophylaxis prescribing adhered to the protocol in 81% of patients. During the first PDSA cycle, adherence increased significantly to 94.5% (86/91 patients), which further increased to 98.7% (74/75 patients) during the second PDSA cycle and remained at 96% (120/125 patients) during the control phase ( < 0.0001).
A multidisciplinary group-designed protocol was successful in standardizing fluconazole prophylaxis prescribing for infants in the level IV NICU. Adherence to protocol was high following implementation and was sustained for the duration of the project. There were no cases of invasive candidiasis noted.
侵袭性念珠菌病在早产儿中具有较高的发病率和死亡率。使用氟康唑进行抗真菌预防可显著降低该人群侵袭性真菌感染的风险。我们注意到在我们的四级新生儿重症监护病房(NICU)中,氟康唑预防用药的情况存在差异,因此试图规范预防性氟康唑的处方。
我们组建了一个多学科团队,利用文献和专家共识制定了一项循证方案,以指导我们四级NICU中氟康唑预防用药的合理使用。在确定方案实施前氟康唑预防用药的基线情况后,我们采用计划-实施-研究-改进(PDSA)循环来引入规范化处方并将其纳入日常实践。在为期6个月的干预阶段之后是为期2年的对照阶段,在此期间每月进行审核以评估方案的依从性。结果显示在统计过程控制图中。
在方案实施前,81%的患者氟康唑预防用药符合方案。在第一个PDSA循环期间,依从性显著提高至94.5%(91例患者中的86例),在第二个PDSA循环期间进一步提高至98.7%(75例患者中的74例),在对照阶段保持在96%(125例患者中的120例)(<0.0001)。
一个多学科团队设计的方案成功地规范了四级NICU中婴儿氟康唑预防用药的处方。实施后方案依从性较高,并在项目期间持续保持。未发现侵袭性念珠菌病病例。